Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Werewolf Therapeutics (HOWL) Shares Outstanding (2021 - 2025)

Werewolf Therapeutics (HOWL) has disclosed Shares Outstanding for 5 consecutive years, with $48.6 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 8.41% to $48.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $48.6 million through Dec 2025, up 8.41% year-over-year, with the annual reading at $48.6 million for FY2025, 8.41% up from the prior year.
  • Shares Outstanding for Q4 2025 was $48.6 million at Werewolf Therapeutics, up from $47.3 million in the prior quarter.
  • The five-year high for Shares Outstanding was $48.6 million in Q4 2025, with the low at $1.8 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $35.5 million, with a median of $35.6 million recorded in 2023.
  • Peak annual rise in Shares Outstanding hit 1471.25% in 2022, while the deepest fall reached 3.22% in 2022.
  • Over 5 years, Shares Outstanding stood at $27.6 million in 2021, then rose by 14.15% to $31.5 million in 2022, then increased by 24.09% to $39.1 million in 2023, then rose by 14.63% to $44.8 million in 2024, then rose by 8.41% to $48.6 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $48.6 million, $47.3 million, and $45.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.